相关实验视频
Updated: Jun 9, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
伟大的期望:塞马格卢提德作为精神病医院的抗糖尿病体重控制药
1Clinical Pharmacy Manager, NewYork-Presbyterian Hospital, New York, NY, USA.
Journal of pharmacy practice
|October 22, 2024
概括
葡萄糖类1 (GLP-1) 受体激动剂在治疗2型糖尿病 (T2D) 和预防精神病患者服用精神药物的体重增加方面表现有前途. 整合这些药物可以减轻代谢副作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 代谢障碍 代谢障碍 代谢障碍
- 精神病学是一个精神病学.
背景情况:
- 精神药物通常会导致体重增加和代谢并发症,特别是在2型糖尿病 (T2D) 患者中.
- 新型抗糖尿病药物,包括葡萄糖类1 (GLP-1) 受体激活剂,提供超出血糖控制的好处,如心血管和脏保护和体重控制.
研究的目的:
- 探索GLP-1受体激动剂在缓解与精神药物使用相关的代谢副作用的潜力,在住院精神病诊所内,T2D患者.
主要方法:
- 病例报告详细介绍了每周使用西马格卢提德在两名患有T2D的慢性精神药物治疗患者中的使用情况.
- 评估治疗患者的血糖水平和体重变化.
主要成果:
- 塞马格卢提德的使用使得这两位患者的血糖水平有所改善.
- 在接受塞马格卢提德与他们的精神药物一起服用的患者中,体重增加被防止.
结论:
- GLP-1受体激动剂代表了在T2D的住院精神病患者群体中管理心理药物的代谢不良影响的可行策略.
- 实施需要考虑综合患者护理的成本,可访问性和机构表单限制.
相关概念视频
Glucagon-like Receptor Agonists
301
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301
Insulin: Dosing Regimen and Adverse Effects
148
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
148
Oral Hypoglycemic Agents: Glinides
142
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
142
Oral Hypoglycemic Agents: Biguanides and Glitazones
176
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
176
Dipeptidyl Peptidase 4 Inhibitors
173
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
173
Antidepressant Drugs: MAOIs and Other Agents
196
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
196

